Search

Your search keyword '"Kaipiainen-Seppänen, Oili"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Kaipiainen-Seppänen, Oili" Remove constraint Author: "Kaipiainen-Seppänen, Oili"
46 results on '"Kaipiainen-Seppänen, Oili"'

Search Results

1. Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank

2. High-Resolution Genotyping of Formalin-Fixed Tissue Accurately Estimates Polygenic Risk Scores in Human Diseases

4. The public health impact of poor sleep on severe COVID-19, influenza and upper respiratory infections

5. Risk of Midlife Stroke After Adverse Pregnancy Outcomes: The FinnGen Study

6. Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women

8. Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank

10. The public health impact of poor sleep on severe COVID-19, influenza and upper respiratory infections

11. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial

14. Clonal Hematopoiesis Associated with Rheumatoid Arthritis

15. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)

17. Association of rheumatoid arthritis disease activity and antibodies to periodontal bacteria with serum lipoprotein profile in drug naive patients

20. Delay to Institution of Therapy and Induction of Remission Using Single-Drug or Combination–Disease-Modifying Antirheumatic Drug Therapy in Early Rheumatoid Arthritis

21. Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial

23. Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial.

25. Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study.

26. High-Resolution Genotyping of Formalin-Fixed Tissue Accurately Estimates Polygenic Risk Scores in Human Diseases

27. Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.

28. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial

30. Failure in Longterm Treatment is Rare in Actively Treated Patients with Rheumatoid Arthritis, But May Be Predicted by High Health Assessment Score at Baseline and by Residual Disease Activity at 3 and 6 Months: The 5-year Followup Results of the...

33. Intensive treatment of rheumatoid arthritis reduces need for dialysis due to secondary amyloidosis.

34. Total Incidence and Distribution of Inflammatory Joint Diseases in a Defined Population: Results from the Kuopio 2000 Arthritis Survey

35. Delay to institution of therapy and induction of remission using single-drug or combination–disease-modifying antirheumatic drug therapy in early rheumatoid arthritis

36. Autologous peripheral blood stem cell transplantation in a patient with severe mixed connective tissue disease.

37. Metabolic Syndrome, Disease Activity, and Adipokines in Patients With Newly Diagnosed Inflammatory Joint Diseases.

38. Profile of initial drug therapy in paediatric systemic lupus erythematosus in Finland, 2000-2007.

39. Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial.

40. Incidence of systemic lupus erythematosus in Finland, 2000-2007, a nationwide study.

41. [Chest, skin and joint symptoms of a middle-aged man].

42. [Adverse muscle effects of a podofyllotoxin-containing cytotoxic drug product with simvastatin].

44. [Not Available].

45. [Epidemiology of rheumatoid arthritis in Finland].

Catalog

Books, media, physical & digital resources